Global Liquid Biopsy Market Outlook, 2029

The global liquid biopsy market is experiencing significant growth, driven by a confluence of factors. The rising incidence and prevalence of cancer, particularly with growing awareness initiatives from global health organizations like the WHO, is a key driver. This growth is fuelled by the increasing preference for non-invasive procedures like liquid biopsies, compared to traditional tissue biopsies which can be painful and carry risks. Within the market, assay kits hold the dominant position due to their cost-effectiveness and minimally invasive nature, making them attractive for cancer screening, monitoring, and treatment throughout a patient's journey. Additionally, the cancer application segment is anticipated to capture the largest market share due to the rising prevalence of cancer and the crucial role liquid biopsies play in understanding cancer signatures and developing personalized therapies.

According to the research report, “Global Liquid biopsy Market Outlook, 2029” published by Bonafide Research, the market is anticipated to grow with 11.50% CAGR by 2024-29. Emerging countries like India, China, and Brazil present lucrative growth opportunities due to factors like a high cancer burden, large patient populations, and improving healthcare infrastructure. However, challenges remain, including the lower sensitivity of certain liquid biopsies and the uncertain reimbursement scenario, which can limit uptake. Despite these hurdles, the future of the liquid biopsy market appears bright. Advancements in technologies like next-generation sequencing (NGS) are enhancing the accuracy of liquid biopsies, while ongoing research and development by established and emerging players is expected to yield novel liquid biopsy solutions. This continuous innovation, coupled with the increasing demand for minimally invasive cancer diagnostic tools, paves the way for a thriving liquid biopsy market in the years to come.

Market Drivers

• Rising Cancer Burden and Awareness: The escalating prevalence of cancer globally, coupled with growing awareness initiatives undertaken by organizations like the WHO, is a key driver. This translates to an increased demand for minimally invasive diagnostic tools like liquid biopsies.
• Preference for Non-invasive Procedures: Liquid biopsies offer a significant advantage over traditional tissue biopsies, which can be painful and carry risks. This growing preference for non-invasive procedures is fueling market expansion.
• Technological Advancements: Developments in next-generation sequencing (NGS) technology are enhancing the accuracy and sensitivity of liquid biopsies. This continuous innovation is leading to the adoption of liquid biopsies in various applications.

Market Trends



• Shifting Focus Towards Early Cancer Detection: Early cancer detection offers a significant advantage in terms of treatment success rates and patient outcomes. The ability of liquid biopsies to detect cancer at earlier stages is driving their adoption in screening programs.
• Growing Focus on Personalized Medicine: Liquid biopsies play a crucial role in personalized medicine by enabling the identification of specific mutations and tailoring treatment plans accordingly. This trend is expected to further propel market growth.
• Expansion into Emerging Markets: Developing economies like India, China, and Brazil present lucrative growth opportunities due to factors like a high cancer burden, large patient populations, and improving healthcare infrastructure.

Market Challenges

• Lower Sensitivity of Certain Liquid Biopsies: The sensitivity of some liquid biopsies, particularly for certain cancer types, remains a challenge. This can lead to false negatives and hinder wider adoption .
• Uncertain Reimbursement Scenario: Limited reimbursement for liquid biopsy tests, particularly for panel-based tests, can restrict their accessibility for patients. This poses a significant challenge for market growth .
• Stringent Regulatory Requirements: The regulatory landscape for liquid biopsies is still evolving. Navigating these stringent requirements can be a hurdle for new market entrants and hinder innovation.

Based on the report the clinical application is segmented into Early Cancer Screening, Therapy Selection, Treatment Monitoring and Recurrence Monitoring. The Treatment monitoring is leading in the liquid biopsy industry due to its ability to provide real-time, minimally invasive monitoring of treatment response, disease progression, and emergence of resistance mutations, thereby guiding personalized treatment strategies and improving patient outcomes.

The realm of liquid biopsy, treatment monitoring has emerged as a pivotal clinical application, revolutionizing cancer management through its capability to deliver actionable insights into treatment response and disease progression in real-time. Liquid biopsy techniques, such as circulating tumor DNA (ct DNA) analysis, circulating tumor cells (CTCs) detection, and extracellular vesicle analysis, offer non-invasive methods to capture and analyze cancer biomarkers present in blood, urine, or other bodily fluids. The primary reason for treatment monitoring's leadership in the liquid biopsy industry lies in its transformative impact on personalized cancer care, enabling oncologists to dynamically assess treatment efficacy, detect early signs of resistance, and tailor therapeutic interventions to individual patient needs. Central to the prominence of treatment monitoring in liquid biopsy is its ability to provide timely and precise information on treatment response. Unlike conventional tissue biopsies, which are invasive and may not reflect the evolving tumor landscape, liquid biopsies offer a minimally invasive alternative that allows for serial monitoring throughout the course of treatment. By detecting changes in ct DNA levels or mutations associated with treatment response, liquid biopsy enables clinicians to assess the effectiveness of therapies such as chemotherapy, targeted therapy, or immunotherapy. This real-time feedback loop empowers oncologists to make informed decisions about adjusting treatment regimens, switching therapies, or implementing combination approaches to optimize patient outcomes. Treatment monitoring through liquid biopsy plays a critical role in identifying minimal residual disease (MRD) and monitoring for disease recurrence post-treatment. MRD refers to small amounts of residual cancer cells that may remain undetected by imaging or clinical examination but can lead to disease relapse. Liquid biopsy techniques excel in detecting residual ctDNA or CTCs indicative of MRD, enabling early intervention strategies such as adjuvant therapy or intensified surveillance to prevent disease recurrence. This proactive approach not only enhances survival rates but also improves quality of life by minimizing the impact of recurrent cancer on patients and their families. Treatment monitoring in the liquid biopsy industry supports the emergence of precision oncology by guiding the selection of targeted therapies based on specific molecular alterations detected in circulating biomarkers. By identifying actionable mutations or resistance mechanisms early in the treatment course, liquid biopsy helps tailor therapies that are more likely to be effective and less toxic, thereby optimizing therapeutic outcomes and reducing unnecessary treatment-related side effects. In addition to its clinical utility, treatment monitoring through liquid biopsy contributes to advancing cancer research and drug development efforts. The ability to longitudinally track genetic changes and tumor evolution in response to treatment provides valuable insights into the mechanisms of drug resistance and disease progression. This knowledge fuels the development of novel therapeutic agents, predictive biomarkers, and innovative treatment strategies aimed at overcoming resistance mechanisms and improving long-term survival outcomes for cancer patients.

Based on the report, the end user segment is segmented into Refer, Hospitals and Physician Laboratories, Academic & Research Centers and Other End Users. The Hospitals and physician laboratories are leading in the liquid biopsy industry due to their pivotal role in providing accessible and timely diagnostic services, integrating liquid biopsy technologies into routine clinical practice, and facilitating personalized cancer care for patients.

Hospitals and physician laboratories have emerged as frontrunners in the liquid biopsy industry, leveraging their infrastructure, clinical expertise, and patient-centric approach to drive widespread adoption and integration of liquid biopsy technologies into everyday clinical practice. The primary reason for their leadership lies in their ability to deliver accessible, reliable, and timely diagnostic services that empower oncologists and healthcare providers to make informed decisions regarding cancer diagnosis, treatment selection, and monitoring of disease progression. Central to the prominence of hospitals and physician laboratories in the liquid biopsy industry is their capability to offer comprehensive diagnostic capabilities within a clinical setting. Liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis, circulating tumor cells (CTCs) detection, and extracellular vesicle analysis, provide non-invasive methods to detect and analyze cancer biomarkers in blood or other bodily fluids. These technologies enable oncologists to obtain real-time insights into the genetic profile of tumors, monitor treatment response, and detect early signs of disease recurrence. By integrating liquid biopsy into routine clinical workflows, hospitals and physician laboratories facilitate timely diagnosis and personalized treatment strategies tailored to the unique molecular characteristics of each patient's cancer. Hospitals and physician laboratories play a crucial role in driving innovation and expanding the clinical utility of liquid biopsy technologies. As early adopters of new diagnostic tools and techniques, they collaborate with researchers and industry partners to validate the clinical utility of liquid biopsy in diverse oncology settings. This collaborative approach supports the development of standardized protocols, quality assurance measures, and evidence-based guidelines for incorporating liquid biopsy into clinical practice. By participating in clinical trials and research studies, hospitals and physician laboratories contribute to advancing scientific knowledge, refining diagnostic algorithms, and expanding the application of liquid biopsy beyond traditional tissue-based biopsies. Hospitals and physician laboratories are integral to advancing patient care through multidisciplinary collaboration and personalized medicine initiatives. Liquid biopsy enables oncologists to tailor treatment regimens based on real-time molecular information, optimizing therapeutic outcomes while minimizing treatment-related toxicity. This patient-centered approach not only improves survival rates but also enhances quality of life by offering patients targeted therapies that are more effective and less invasive compared to conventional treatments. Hospitals and physician laboratories also provide ongoing support and counseling to patients and their families, helping them navigate treatment decisions and understand the implications of liquid biopsy results in the context of their cancer journey. The infrastructure and resources available in hospitals and physician laboratories facilitate the scalability and accessibility of liquid biopsy technologies across diverse patient populations. With established networks for specimen collection, processing, and analysis, these healthcare settings ensure efficient turnaround times and reliable test results, essential for timely clinical decision-making. This accessibility promotes equitable access to advanced diagnostic services, regardless of geographical location or socioeconomic status, thereby democratizing precision oncology and improving cancer care outcomes on a global scale.

North America is leading in the liquid biopsy industry due to its robust healthcare infrastructure, early adoption of innovative technologies, significant investment in biomedical research, and supportive regulatory environment that fosters rapid development and commercialization of liquid biopsy technologies.

North America has established itself as a global leader in the liquid biopsy industry, driven by a convergence of factors that position the region at the forefront of innovation, research, and clinical adoption of liquid biopsy technologies. The primary reason for North America's leadership lies in its advanced healthcare infrastructure, which encompasses a network of world-class hospitals, research institutions, and biomedical companies dedicated to advancing cancer diagnostics and personalized medicine. Central to North America's prominence in the liquid biopsy industry is its robust healthcare system, characterized by comprehensive cancer centers and physician practices equipped with state-of-the-art diagnostic facilities. These healthcare settings have embraced liquid biopsy technologies, such as circulating tumor DNA (ctDNA) analysis, circulating tumor cells (CTCs) detection, and exosome analysis, integrating them into routine clinical practice for cancer diagnosis, treatment monitoring, and early detection of disease recurrence. This widespread adoption is facilitated by the region's healthcare policies and reimbursement frameworks that support the incorporation of innovative diagnostic tools into standard patient care pathways, ensuring access to cutting-edge technologies for oncologists and patients alike. North America's early adoption of innovative technologies and its supportive regulatory environment play pivotal roles in driving the growth of the liquid biopsy industry. The region boasts a robust ecosystem of biomedical research institutions, biotechnology companies, and academic centers at the forefront of developing and validating liquid biopsy technologies. Collaborations between researchers, clinicians, and industry stakeholders fuel the translation of scientific discoveries into clinical applications, accelerating the development and commercialization of new liquid biopsy assays and platforms. Regulatory bodies such as the FDA in the United States and Health Canada provide clear pathways for regulatory approval and market access, ensuring that innovative liquid biopsy technologies meet rigorous standards of safety, efficacy, and quality before reaching patients. North America's leadership in biomedical research and clinical trials further enhances its position in the liquid biopsy industry. The region attracts substantial investments in cancer research, biomarker discovery, and clinical validation studies, fostering a rich pipeline of innovative liquid biopsy technologies. Research initiatives focus on refining diagnostic accuracy, expanding the utility of liquid biopsy beyond traditional tissue biopsies, and exploring new biomarkers that could revolutionize cancer detection and treatment. These efforts not only drive scientific advancement but also contribute to the development of personalized treatment strategies based on molecular profiling, improving outcomes and quality of life for cancer patients. North America's strong emphasis on collaboration and knowledge-sharing within the healthcare and scientific communities promotes continuous innovation and adaptation of liquid biopsy technologies to meet evolving clinical needs. Academic centers and research hospitals collaborate with industry partners to conduct multicenter studies, validate biomarkers, and establish clinical utility guidelines for liquid biopsy in various cancer types. This collaborative approach enhances the reliability and clinical validity of liquid biopsy tests, paving the way for broader acceptance and integration into oncology practice across diverse patient populations.

• In August 2022, Thermo Fisher Scientific Inc. (US) launched the first NGS-based assays (Ion Torrent Oncomine Myeloid MRD Assays) capable of analyzing both DNA and RNA. This innovation enables comprehensive and highly sensitive assessments of measurable residual disease (MRD) in myeloid malignancies using blood and bone marrow samples.
• In May 2022, QIAGEN N.V. (Netherlands) introduced the therascreen EGFR Plus RGQ PCR Kit. This novel in vitro diagnostic test offers sensitive and accurate analysis of EGFR mutations, aiding in the diagnosis and treatment of specific cancers.
• In June 2021, Guardant Health, Inc. (US) launched the Guardant360 Response test. This innovative test detects changes in circulating tumor DNA (ctDNA) levels, providing valuable insights into treatment response and disease progression.
• In October 2020, F. Hoffmann-La Roche Ltd. (Switzerland) received US FDA approval for expanded claims associated with their cobas EGFR Mutation Test v2. This diagnostic test can now be used as a companion diagnostic (CDx) for a broader range of therapies targeting non-small cell lung cancer (NSCLC).

Considered in this report
• Historic year: 2018
• Base year: 2023
• Estimated year: 2024
• Forecast year: 2029

Aspects covered in this report
• Liquid Biopsy market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology
• Multi-gene Parallel Analysis using NGS
• Single-gene Analysis using PCR Microarrays

By End User
• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic & Research Centers
• Other End Users

The approach of the report:
This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Liquid Biopsy industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.